Molecular Profiling and Tumor Biomarker Analysis of GOG281/LOGS: A Positive Late-Phase Trial of Trametinib for Recurrent/Persistent Low-Grade Serous Ovarian Carcinoma
This exploratory analysis suggests that pERK expression and mutation of KRAS/BRAF/NRAS are candidate biomarkers of improved PFS and response to trametinib, respectively.
Authors
- Peter G. Rose (ORCID: https://orcid.org/0000-0003-2676-0166)
- Robert L. Hollis (ORCID: https://orcid.org/0000-0002-1390-3298)
- Robert Louis Coleman (ORCID: https://orcid.org/0000-0001-9343-8754)
- Charlie Gourley (ORCID: https://orcid.org/0000-0002-2377-7221)
- Kwong‐Kwok Wong (ORCID: https://orcid.org/0000-0002-0375-6669)
- Mitchell I. Edelson (ORCID: https://orcid.org/0000-0001-6708-7380)
- David M. Gershenson (ORCID: https://orcid.org/0000-0001-9712-2140)
- Ailith Ewing (ORCID: https://orcid.org/0000-0002-2272-1277)
- David M. O’Malley (ORCID: https://orcid.org/0000-0002-2828-0177)
- John K. Chan (ORCID: https://orcid.org/0000-0003-3379-6829)
- Andrea R. Hagemann (ORCID: https://orcid.org/0000-0002-3484-0046)
- Stéphanie Gaillard (ORCID: https://orcid.org/0000-0002-2174-3693)
- Heather A. Lankes (ORCID: https://orcid.org/0000-0001-8814-5033)
- Karen Carty (ORCID: https://orcid.org/0000-0001-5040-6381)
- Michael Churchman (ORCID: https://orcid.org/0000-0003-1958-7692)
- Saketh R. Guntupalli (ORCID: https://orcid.org/0000-0003-2570-6635)
- WILLIAM H. RODGERS (ORCID: https://orcid.org/0009-0002-1247-3107)
- Angeles Alvarez Secord (ORCID: https://orcid.org/0000-0003-0946-7662)
- Susana Banerjee (ORCID: https://orcid.org/0000-0002-8840-7934)
- C. Simon Herrington (ORCID: https://orcid.org/0000-0001-9177-8165)
- Kathleen N. Moore (ORCID: https://orcid.org/0000-0002-5803-0718)
- Oliver Dorigo (ORCID: https://orcid.org/0000-0002-1976-5201)
- Austin Miller (ORCID: https://orcid.org/0000-0001-9739-8462)
- Anil K. Sood (ORCID: https://orcid.org/0000-0003-4242-1762)
- David Millan (ORCID: https://orcid.org/0000-0001-9302-8982)
Institutions
- Sutter Health (US)
- Gynecologic Oncology Group (US)
- Roswell Park Comprehensive Cancer Center (US)
- Cleveland Clinic (US)
- Royal Marsden NHS Foundation Trust (GB)
- The University of Texas MD Anderson Cancer Center (US)
- Johns Hopkins University (US)
- Washington University in St. Louis (US)
- Cornell University (US)
- Cleveland Foundation (US)
- Johns Hopkins Medicine (US)
- The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (US)
- Beatson West of Scotland Cancer Centre (GB)
- Edinburgh Cancer Research (GB)
- The Ohio State University Wexner Medical Center (US)
- Abington Memorial Hospital (US)
- Clinical Research Institute (US)
- Queen Elizabeth Hospital (GB)
- Queen Elizabeth Hospital (GB)
- Ohio State University Hospital (US)
- Royal Marsden Hospital (GB)
- Duke Institute for Health Innovation (US)
- Duke Medical Center (US)
- Oklahoma State University Oklahoma City (US)
- University of Colorado Cancer Center (US)
- Cancer Research UK Clinical Trials Unit (GB)
- Stanford Medicine (US)
- Johns Hopkins Hospital (US)
- The US Oncology Network (US)
- Queen Elizabeth University Hospital (GB)
- Institute of Genetics and Cancer (GB)
- NRG Oncology (US)
- Sidney Kimmel Comprehensive Cancer Center (US)
- University of Oklahoma Health Sciences Center (US)
- University of Colorado Anschutz Medical Campus (US)
- University of Glasgow (GB)
- University of Colorado Denver (US)
- Stanford University (US)
- University of Edinburgh (GB)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2025-12-11
- DOI
- https://doi.org/10.1158/1078-0432.ccr-25-3042
- Primary Topic
- Ovarian cancer diagnosis and treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00